A Battery-Free Patch on the Fingertip Tracks the Main Parkinson's Drug Through Sweat

Parkinson's care isn't stuck because doctors lack drugs. It is stuck because the standard Parkinson's medication, levodopa, has a therapeutic window that shrinks to roughly two hours as the disease progresses, and the only available readout is the patient's own diary. A team at UC San Diego has built the first battery-free tool that measures that window in real time, from sweat on a fingertip.

Too little and the patient can barely move, a freezing state called hypokinesia. Too much and the body jerks uncontrollably, a side effect called dyskinesia. Clinicians time refills from how patients describe their day, then check blood occasionally in a lab. That approach misses the dangerous gaps where drug levels swing between those two failure modes, especially late in the disease, when the window is narrowest.

The device, described this week in PNAS, is a soft patch that sits on a fingertip and runs without a battery. The fingertip is the load-bearing choice: it has one of the highest densities of eccrine sweat glands on the body, so it can fuel a small enzymatic biosensor and produce a measurable voltage at the same time. An absorbent hydrogel of salts and benign solvents pulls sweat osmotically into a paper serpentine channel, where the enzyme reacts with levodopa and the reaction powers a wireless transmitter that beams the reading to a phone. The full mechanism, from hydrogel to voltage, is the engineering point. It is also why no battery is needed: the chemical reaction that detects the drug is the same one that powers the readout.

In tests on 3 to 5 healthy volunteers and 4 people with Parkinson's, sweat levodopa tracked blood levodopa measured by high-performance liquid chromatography, the standard lab method. The match is what makes the patch clinically useful rather than just a sensor. The data also surfaced a smaller, more provocative finding. Individuals with Parkinson's cleared levodopa from their systems significantly faster than healthy volunteers. The authors frame that as a mechanism behind the crashes patients describe between doses, an early result, not a population estimate, and one that has to be confirmed in larger studies.

The roadmap is closed-loop dosing: the patch reads the drug, a pump adjusts the dose, and the patient gets the right amount without manually timing pills. That vision sits in the paper as a future step, not a deployed product. The patch is research-stage, not FDA-cleared, and the cohort is too small to set population-level dosing rules. The team, led by postdoctoral researcher Tamoghna Saha and senior author Joseph Wang of the Aiiso Yufeng Li Family Department of Chemical and Nano Engineering at UC San Diego, with neurologist Irene Litvan as clinical collaborator, plans larger PD cohorts and longer wear times next. A related Wang-lab sweat sensor for broader metabolic monitoring appeared in Nature Electronics in September.

The two-hour window is the bottleneck Parkinson's care has been navigating blind. The patch is the first tool that promises to make that window visible to a patient at home, every hour of the day, with no needle and no battery. The next runs are larger Parkinson's cohorts and longer wear times. If those hold, the two-hour window stops being something patients navigate by feel and becomes something they can see.